|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-8-23
|
|
pubmed:abstractText |
In a phase I study the feasibility, toxicity and immunological effects of peri-operative cytokine immunotherapy of renal cell carcinoma were studied. Main goals were to determine the maximal tolerable dose and detailed in situ analysis of tumor infiltrates.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0302-2838
|
|
pubmed:author |
pubmed-author:BatchelorDianeD,
pubmed-author:BexAxelA,
pubmed-author:DellemijnTreesT,
pubmed-author:HorenblasSimonS,
pubmed-author:MeinhardtWillemW,
pubmed-author:NooijenWillemW,
pubmed-author:SeinJohanJ,
pubmed-author:VerraNataschaN,
pubmed-author:Vyth-DreeseFlorryF,
pubmed-author:de GastGijsbertG,
pubmed-author:de JongDaphneD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
527-33
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16115526-Adult,
pubmed-meshheading:16115526-Carcinoma, Renal Cell,
pubmed-meshheading:16115526-Combined Modality Therapy,
pubmed-meshheading:16115526-Dendritic Cells,
pubmed-meshheading:16115526-Female,
pubmed-meshheading:16115526-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:16115526-Humans,
pubmed-meshheading:16115526-Immunoenzyme Techniques,
pubmed-meshheading:16115526-Immunotherapy,
pubmed-meshheading:16115526-Interferon-alpha,
pubmed-meshheading:16115526-Interleukin-2,
pubmed-meshheading:16115526-Kidney Neoplasms,
pubmed-meshheading:16115526-Male,
pubmed-meshheading:16115526-Microscopy, Confocal,
pubmed-meshheading:16115526-Middle Aged,
pubmed-meshheading:16115526-Nephrectomy,
pubmed-meshheading:16115526-Staining and Labeling,
pubmed-meshheading:16115526-T-Lymphocytes,
pubmed-meshheading:16115526-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
|
|
pubmed:affiliation |
Department of Immunology, Netherlands Cancer Institute, Amsterdam.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
